COMPANY PROFILE

Cardioxyl Pharmaceuticals

Request full access

Develops and commercializes therapies for the treatment of cardiovascular disease

Chapel Hill, United StatesFounded 2005Biotech & Life Sciences

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for cardiovascular diseases, particularly heart failure and arrhythmias. The company operates in the biopharmaceutical market, targeting healthcare providers and patients who suffer from severe cardiovascular conditions. Cardioxyl's business model revolves around research and development (R&D) of novel drug candidates, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, either directly or through partnerships with larger pharmaceutical companies. The company leverages its expertise in cardiovascular biology and medicinal chemistry to create treatments that address unmet medical needs, aiming to improve patient outcomes and quality of life.

MoreLess Source: Dealroom company data

At a glance

Founded: 2005
Headquarters: Chapel Hill, United States
Sector: Biotech & Life Sciences
Outcome tier: Unicorn$1–10B valuation tier

Knowledge graph

Founder mafias, market maps, lists and research connected to this company by Dealroom

Market maps in Biotech & Life Sciences

Market map Rare Disease Therapeutics & Technologies Landscape

Market map Peptides: The Next Drug Modality Stack Apr 10, 2026

Market map 1k+ Global Genetics & Genomics startups

Unicorn lists

Biotech & Life Sciences unicorns Unicorn list Biotech & Life Sciences unicorns Unicorns in United States Unicorn list Unicorns in United States

Open roles

Track hiring at Cardioxyl PharmaceuticalsOpen roles, team growth and hiring by functionBook a demo

Looking for a job? The startup jobs board lists open roles.Startups hiring now →

Cardioxyl Pharmaceuticals in the Chapel Hill ecosystem

Live from Dealroom

The Cardioxyl Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

NENEA
AFAurora Funds
OROrbiMed
OPOsage University Partners

Series B and later2 investors entered at this stage

OPOsage University Partners
OROrbiMed

Talent

Book a demo to see the people

Team profiled 11 named & role-tagged

Founders /100 quality score

Key operators 7 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Patents

Estimated portfolio value

$33M

16 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cardioxyl Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cardioxyl Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles